Walgreens Boots Alliance, Inc. (WBA): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique des soins de santé et de la vente au détail, Walgreens Boots Alliance (WBA) apparaît comme une puissance transformatrice, mélangeant parfaitement les services de pharmacie traditionnels avec des solutions de santé numérique de pointe. En tirant stratégiquement un modèle commercial complexe qui couvre les marchés mondiaux, la WBA s'est positionnée comme plus qu'une simple pharmacie - c'est un écosystème de santé complet qui relie les patients, les prestataires et les technologies de bien-être grâce à des canaux innovants et des expériences personnalisées. Cette plongée profonde dans le canevas des modèles commerciaux de la WBA révèle le cadre stratégique sophistiqué qui stimule l'un des plus grands détaillants de pharmacie et de santé au monde.

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: partenariats clés

Alliance stratégique avec Amerisourcebergen

Walgreens Boots Alliance détient une participation de 30% dans Amerisourcebergen Corporation. Au cours de l'exercice 2023, le partenariat a généré 25,4 milliards de dollars de revenus de distribution pharmaceutique. L'Alliance stratégique fournit des services de distribution pharmaceutique aux États-Unis.

Détails du partenariat	Métriques financières
Pieu de propriété	30% dans Amerisourcebergen
Revenus de distribution	25,4 milliards de dollars (2023)
Durée du partenariat	En cours depuis 2013

Fabricants pharmaceutiques et partenaires de développeurs de médicaments

Walgreens collabore avec plusieurs fabricants pharmaceutiques pour assurer l'approvisionnement et la distribution des médicaments.

• Pfizer: Partenaire de distribution des vaccins Covid-19
• Johnson & Johnson: Vaccination et collaboration de la chaîne d'approvisionnement pharmaceutique
• Moderna: réseau de distribution de vaccins

Collaborations d'entreprise de technologie de santé

Walgreens possède des partenariats technologiques stratégiques avec les sociétés de santé numérique:

Partenaire technologique	Focus de la collaboration
Microsoft	Cloud Computing et Solutions de santé numérique
Villageois	Développement de la clinique de soins primaires
Santé Teladoc	Intégration du service de télésanté

Partenariats internationaux de réseau de pharmacie et de santé

Walgreens Boots Alliance exploite des partenariats internationaux grâce à son réseau mondial.

• Bottes d'alliance (Royaume-Uni): Réseau de vente au détail de pharmacie
• Sinopharm Holding Group (Chine): Distribution pharmaceutique
• Farmacias Benavides (Mexique): Expansion de la pharmacie au détail

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: activités clés

Opérations de pharmacie au détail dans plusieurs pays

En 2024, Walgreens Boots Alliance exploite 9 021 emplacements de pharmacie au détail aux États-Unis et à l'étranger. La société gère 8 965 magasins aux États-Unis et 56 magasins à l'étranger.

Pays	Nombre de magasins	Services de pharmacie
États-Unis	8,965	Remplissage sur ordonnance, services de santé
Marchés internationaux	56	Retail pharmacie, services de santé

Distribution pharmaceutique et services de gros

La WBA génère 25,4 milliards de dollars de revenus de gros pharmaceutique en gros et de distribution grâce à son partenariat Amerisourcebergen, ce qui représente 15,3% du total des revenus de l'entreprise.

Services de santé et solutions de santé numérique

• Plateforme de soins virtuels desservant 4,2 millions de consultations en santé numérique en 2023
• Services de télésanté intégrés dans 50 États
• Plateforme de gestion des ordonnances numériques avec 12,3 millions d'utilisateurs actifs

Gestion des médicaments sur ordonnance

Métrique	Volume annuel
PRESCRIPTIONS TOTALES REMPLÉES	1,08 milliard
Transferts de prescription numérique	376 millions
Programmes d'adhésion aux médicaments	287 millions d'interventions

Merchandising et gestion des stocks de vente au détail

La WBA gère un portefeuille d'inventaire d'une valeur de 17,6 milliards de dollars, avec 45 000 SKU de produits uniques dans tous les catégories de soins de santé, de bien-être et de vente au détail.

Catégorie de produits	Valeur d'inventaire	Pourcentage du total
Médicaments	8,3 milliards de dollars	47%
Santé et bien-être	5,7 milliards de dollars	32%
Produits de consommation de vente au détail	3,6 milliards de dollars	21%

Walgreens Boots Alliance, Inc. (WBA) - Modèle commercial: Ressources clés

Réseau étendu d'emplacements de pharmacie

Depuis 2024, Walgreens fonctionne 9 021 emplacements de pharmacie au détail aux États-Unis. La société maintient 8 618 magasins aux États-Unis et 403 emplacements sur les marchés internationaux.

Type d'emplacement	Nombre de magasins
Pharmacies de vente au détail aux États-Unis	8,618
Lieux internationaux	403
Emplacements totaux de pharmacie	9,021

Plates-formes et technologies de santé numériques avancées

Walgreens a investi 1,2 milliard de dollars en technologies de santé numérique en 2023. Les plates-formes numériques clés comprennent:

• Application mobile Walgreens
• Système de gestion de la pharmacie sur les prescription numérique
• Plateforme de services de télésanté

Solide réputation de la marque dans la vente au détail pharmaceutique

Valeur de la marque Walgreens estimée à 15,3 milliards de dollars en 2024, classement 37e de la valeur de la marque parmi les marques de vente au détail mondiales.

Professionnels et pharmaciens de la santé qualifiés

Walgreens emploie Environ 283 000 employés au total, avec Plus de 62 000 pharmaciens agréés à travers son réseau.

Catégorie des employés	Nombre d'employés
Total des employés	283,000
Pharmaciens agréés	62,000

Infrastructure de chaîne d'approvisionnement robuste

Walgreens maintient 22 centres de distribution aux États-Unis, avec une capacité de distribution annuelle de 132 milliards de dollars en produits pharmaceutiques et commerciaux.

• Emplacements du centre de distribution total: 22
• Capacité de distribution annuelle: 132 milliards de dollars
• Technologie de gestion des stocks: systèmes avancés de RFID et de l'IA-AI

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: propositions de valeur

Services de santé pratiques et accessibles

Au T1 2024, Walgreens exploite 9 021 emplacements de pharmacie au détail aux États-Unis. L'entreprise fournit:

• Services de clinique sans rendez-vous dans plus de 400 emplacements de la clinique de soins de santé
• Covid-19 et services de vaccination de routine dans 8 945 magasins
• Consultations de télésanté numérique 24/7 via la plate-forme Express Care Online

Type de service	Interactions annuelles des patients	Coût moyen
Visites de clinique en magasin	5,2 millions	$85-$125
Télésanté numérique	3,7 millions	$49-$79

Solutions complètes de médicaments et de bien-être

Les services pharmaceutiques Walgreens comprennent:

• Gestion des médicaments sur ordonnance pour 350 millions d'ordonnances annuelles
• Gestion de la thérapie médicamenteuse pour 2,5 millions de patients
• Services de pharmacie spécialisés générant 22,3 milliards de dollars de revenus annuels

Expériences de pharmacie numérique et physique intégrée

Métriques de plate-forme numérique:

• Application mobile Walgreens avec 70 millions d'utilisateurs actifs
• Taux de recharge de prescription numérique: 45% du total des prescriptions
• Revenus de services de santé en ligne: 1,6 milliard de dollars en 2023

Offres de produits de santé et de bien-être personnalisés

Catégorie de produits	Ventes annuelles	Part de marché
Produits de bien-être de marque privée	3,4 milliards de dollars	12.5%
Suppléments de santé	1,9 milliard de dollars	8.7%

Programmes de prix compétitifs et de fidélisation de la clientèle

Détails du programme de fidélité:

• Programme d'équilibre des récompenses avec 87 millions de membres actifs
• Économies moyennes des clients: 268 $ par an
• Remption de coupons numériques: 42% du total des transactions

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: relations avec les clients

Programmes de fidélité et suivi de la santé personnalisé

Le programme Walgreens Balance Rewards comptait 89 millions de membres actifs en 2022. Le programme génère environ 16,5 milliards de dollars de revenus de fidélisation des clients chaque année. Les membres reçoivent un suivi de la santé personnalisé via l'application, avec plus de 4,5 millions de participants à un suivi de la santé numérique active.

Métrique du programme de fidélité	Valeur
Membres actifs	89 millions
Revenus de fidélité	16,5 milliards de dollars
Utilisateurs de suivi de la santé numérique	4,5 millions

Plateformes de gestion de prescription numérique

Processus de plate-forme de prescription numérique Walgreens 350 millions d'ordonnances par an. L'application mobile compte 70 millions d'utilisateurs enregistrés avec des capacités de gestion de prescription numérique.

• Demandes de recharge de prescription numérique: 42% des interactions totales de prescription
• Connects mensuels moyens de l'application: 12,3 millions
• Prise en charge de la prescription numérique: Disponible dans 9 021 emplacements de pharmacie

Services de consultation et de dépistage de la santé en magasin

Walgreens effectue environ 5,2 millions de dépistages de santé par an sur ses 9 021 emplacements. La société propose Administration des vaccins à 8 700 magasins.

Service de santé	Volume annuel
Projections de santé	5,2 millions
Lieux de vaccination	8,700

Application mobile et support client en ligne

L'application mobile Walgreens compte 70 millions d'utilisateurs enregistrés avec une note de 4,7 étoiles. Le support client gère environ 22 millions d'interactions numériques mensuellement.

• Taux de téléchargement des applications mobiles: 2,3 millions de nouveaux utilisateurs par trimestre
• Disponibilité du support de chat en ligne: 24/7
• Temps de réponse du service client numérique moyen: 8 minutes

Engagement continu en santé et communication de bien-être

Walgreens envoie 145 millions de points de contact personnalisés de communication pour la santé trimestriels, 68% des clients recevant des recommandations de bien-être ciblées.

Métrique de l'engagement	Valeur
Points de contact trimestriels de communication	145 millions
Les clients recevant des recommandations ciblées	68%

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: canaux

Emplacements de pharmacie physique

Au T1 2024, Walgreens exploite 9 021 emplacements de pharmacie au détail aux États-Unis.

Type d'emplacement	Nombre de magasins
Magasins Walgreens (États-Unis)	9,021
Boots Pharmacies (Royaume-Uni)	2,172
Lieux internationaux	517

Plateformes de commerce électronique en ligne

Walgreens.com génère environ 5,2 milliards de dollars de ventes numériques annuelles à partir de 2023.

• Taux de croissance des ventes numériques: 27% d'une année sur l'autre
• Recharges sur ordonnance en ligne: 68% du volume total de prescription
• Base de clients numériques: 94 millions d'utilisateurs enregistrés

Application mobile

Les téléchargements de l'application mobile Walgreens ont atteint 45,3 millions d'utilisateurs actifs en 2023.

Métrique de l'application	Valeur
Total des téléchargements d'applications	45,3 millions
Utilisateurs actifs mensuels	22,7 millions

Services de télésanté

La plate-forme de soins virtuels de Walgreens a effectué 3,2 millions de consultations de télésanté en 2023.

• Coût moyen de consultation en télésanté: 49 $
• Couverture des services de télésanté: 48 États
• Durée moyenne de la consultation: 12 minutes

Support client en magasin et numérique

Le support client de Walgreens gère 12,5 millions d'interactions clients mensuellement.

Canal de support	Interactions mensuelles
Support en magasin	6,3 millions
Support numérique	4,7 millions
Support téléphonique	1,5 million

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: segments de clientèle

Consommateurs de pharmacie au détail

En 2023, Walgreens dessert environ 9 millions de clients par jour dans 9 021 emplacements de vente au détail aux États-Unis. La valeur moyenne de la transaction client est de 24,37 $.

Client démographique	Pourcentage
18-34 ans	22%
35 à 54 ans	35%
55 ans et plus	43%

Professionnels de la santé

Walgreens soutient environ 250 000 professionnels de la santé grâce à ses services et partenariats pharmaceutiques.

• Pharmaciens servis: 135 000
• Réseau des médecins: 75 000
• Infirmières praticiennes: 40 000

Patients atteints de maladies âgées et chroniques

Walgreens sert environ 15 millions de patients souffrant de maladies chroniques, avec un accent significatif sur les populations de Medicare et Medicaid.

Condition chronique	Population de patients
Diabète	4,2 millions
Hypertension	5,6 millions
Maladie cardiaque	3,1 millions

Clients de santé des entreprises et institutionnelles

Walgreens gère les services de santé pour plus de 500 clients d'entreprises et partenaires institutionnels, générant 12,4 milliards de dollars de revenus de soins de santé d'entreprise en 2023.

• Fortune 500 Clients d'entreprise: 175
• Partenariats du système de santé: 250
• Valeur du contrat de santé des entreprises annuelles: 24,8 millions de dollars moyens

Individus axés sur le bien-être

Walgreens cible environ 35 millions de consommateurs soucieux de leur santé grâce à ses programmes de bien-être et à ses plateformes de santé numérique.

Segment du bien-être	Base d'utilisateurs
Utilisateurs de la plate-forme de santé numérique	8,2 millions
Clients de compléments nutritionnels	6,5 millions
Programme de suivi du fitness	4,3 millions

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: Structure des coûts

Achat d'inventaire pharmaceutique

Total des coûts d'approvisionnement en stock pharmaceutique pour l'exercice 2023: 59,1 milliards de dollars

Catégorie d'inventaire	Coût annuel
Médicaments sur ordonnance	42,3 milliards de dollars
Médicaments en vente libre	8,7 milliards de dollars
Fournitures médicales	8,1 milliards de dollars

Exploitations et entretien des magasins de détail

Total des frais d'exploitation annuels des magasins de détail: 22,6 milliards de dollars

• Nombre de magasins de détail: 9 021
• Coût de maintenance du magasin moyen par emplacement: 2,5 millions de dollars par an
• Gestion des services publics et des installations: 3,4 milliards de dollars

Salaires des employés et rémunération professionnelle des soins de santé

Compensation annuelle totale des employés: 18,3 milliards de dollars

Catégorie des employés	Compensation annuelle
Personnel de vente au détail	7,6 milliards de dollars
Pharmaciens	4,9 milliards de dollars
Employés d'entreprise	5,8 milliards de dollars

Technologie et développement de plate-forme numérique

Investissement total de technologie annuelle: 1,2 milliard de dollars

• Développement de la plate-forme numérique: 650 millions de dollars
• Infrastructure de cybersécurité: 280 millions de dollars
• Maintenance de la plate-forme de commerce électronique: 270 millions de dollars

Frais de marketing et d'acquisition des clients

Dépenses de marketing annuelles totales: 2,7 milliards de dollars

Canal de marketing	Dépenses annuelles
Marketing numérique	1,1 milliard de dollars
Publicité traditionnelle	890 millions de dollars
Programmes de fidélisation de la clientèle	710 millions de dollars

Walgreens Boots Alliance, Inc. (WBA) - Modèle d'entreprise: Strots de revenus

Ventes de médicaments sur ordonnance

Au cours de l'exercice 2023, Walgreens Boots Alliance a déclaré des ventes de médicaments sur ordonnance de 122,0 milliards de dollars. La société a traité environ 1,1 milliard d'ordonnances au cours de cette période.

Segment de prescription	Revenus (milliards de dollars)	Pourcentage du total des revenus
Ventes de prescription de vente au détail	86.5	39.2%
Pharmaceutique en gros	35.5	16.1%

Revenus de produits en vente libre

Les ventes de produits en vente libre (OTC) ont généré 18,4 milliards de dollars de revenus pour Walgreens au cours de l'exercice 2023.

• Les meilleures catégories de produits en vente libre comprennent:
• Médicaments contre la douleur
• Traitements du froid et de la grippe
• Vitamines et suppléments
• Produits de soins personnels

Services de santé et consultations

Les revenus des services de santé ont atteint 5,2 milliards de dollars au cours de l'exercice 2023, avec une croissance significative de:

Type de service	Revenus (million de dollars)
Vaccinations Covid-19	1.6
Immunisations de routine	1.1
Services de clinique	2.5

Distribution de gros pharmaceutique

La distribution de gros pharmaceutique par Alliance Healthcare a généré 35,5 milliards de dollars de revenus pour l'exercice 2023.

• Couverture internationale de la distribution pharmaceutique dans 13 pays
• Desservant plus de 170 000 pharmacies et prestataires de soins de santé

Plateforme de santé numérique et services technologiques

Les revenus de la plate-forme de santé numérique ont totalisé 2,3 milliards de dollars au cours de l'exercice 2023.

Service numérique	Revenus (million de dollars)
Recharges sur ordonnance en ligne	850
Consultations de télésanté	750
Surveillance de la santé numérique	700

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Value Propositions

You're looking at the core reasons customers choose Walgreens Boots Alliance, Inc. (WBA) over the competition right now. It's about blending the local corner store feel with sophisticated healthcare delivery, so you get both convenience and specialized medical support.

Convenient, trusted, and accessible local healthcare destination.

Walgreens Boots Alliance, Inc. maintains a massive physical footprint, which is a key part of its value. As of March 2025, you could find over 8,700 Walgreens locations across the U.S.. This physical presence is augmented by digital health services, offering virtual care in 30 states, making that care accessible to nearly 90% of the U.S. population. The company is actively optimizing this footprint, planning to close 500 stores in fiscal year 2025 as part of a larger Footprint Optimization Program.

The value proposition here is accessibility, supported by:

• Over 8,700 U.S. Walgreens locations as of March 2025.
• Virtual care available in 30 states.
• Delivery options, including two-hour service from approximately 800 stores.

Integrated primary care and specialty pharmacy services (Shields Health Solutions).

The integration of Shields Health Solutions is central to WBA's high-value healthcare offering, especially for complex, high-cost medications. Shields works directly with health systems to manage their specialty pharmacy needs. This business unit partners with more than 80 health system partners nationwide, which represents approximately 1,000 hospitals. The impact on payer access is significant; Shields has unlocked $11B of incremental payer access since 2021.

Here's a look at some of the operational and financial outcomes Shields delivers for its partners:

Metric	Value/Rate	Context
Incremental Payer Access Unlocked (Since 2021)	$11B	Total value unlocked for health systems
Health System Partners	Over 80	Number of partners nationwide
Average Time to Therapy	~2 days	Operational efficiency metric
Medication Adherence Rates	92.3%	Clinical outcome metric
Projected Partner Pharmacy Growth	35-40%	Sustainable growth driven by the care model

The goal is to accelerate specialty pharmacy success by breaking down barriers to affordable care, so you see improved patient outcomes and system-wide growth.

One-stop shop for prescription drugs, over-the-counter (OTC) medicine, and retail essentials.

The traditional retail component remains a core value, though it's increasingly balanced by pharmacy volume. In the first quarter of fiscal year 2025, comparable pharmacy sales grew 12.7%, driven by brand inflation and prescription volume. To be fair, comparable retail sales decreased 2.4% in Q3 2025, impacted by weaker sales in grocery, household, health and wellness, and beauty. However, the pharmacy side is robust, with total prescriptions filled (including immunizations, adjusted to 30-day equivalents) reaching 316.3 million in Q1 FY2025.

Key prescription volume statistics from Q1 FY2025 include:

• Total prescriptions filled (30-day equivalent): 316.3 million.
• Comparable prescriptions filled (excluding immunizations): Growth of 3.5%.
• Comparable pharmacy sales growth: 12.7%.

Personalized value and offers through the myWalgreens rewards program.

The myWalgreens program is designed to be a personalized digital platform, moving beyond the old points system to offer direct cash rewards. Members earn 1 percent in Walgreens Cash rewards on most eligible purchases made in-store and online, including pharmacy prescriptions and services (with some state exceptions). For WBA's own products, the reward is higher at 5 percent in Walgreens Cash rewards on Walgreens-branded items.

This focus on own-brand products is a deliberate strategy to boost profitability, as seen in the penetration rate:

Metric	Value
Own-Brand Penetration (Q1 FY2025)	17.8%
Increase in Penetration (Basis Points)	75
Planned New Own-Brand Products (FY2025)	Over 300

The program also drives engagement through personalized offers and regional alerts based on location and shopping habits, helping to tailor the value proposition to the individual you.

High-volume prescription capacity, filling 316.3 million scripts in Q1 FY2025.

This number underscores the sheer scale of WBA's dispensing operation. The 316.3 million total prescriptions filled in Q1 FY2025, adjusted to 30-day equivalents, represents a 1.5% increase year-over-year. This high volume is supported by operational improvements, such as Micro-Fulfillment Centers (MFCs) serving approximately 4,800 stores, which saw shipped volumes up 23% year-on-year, and a cost-to-fill down 13%. These efficiencies help free up pharmacists for clinical services.

Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Customer Relationships

The relationship Walgreens Boots Alliance, Inc. (WBA) maintains with its customers is segmented by the service being delivered, moving from highly automated transactions to dedicated, personal care interactions.

Automated, transactional relationship for prescription refills and retail purchases

For routine prescription fulfillment, Walgreens Boots Alliance, Inc. relies heavily on centralized automation to process high volumes, creating a fast, transactional touchpoint for the majority of refills. The company has been aggressively scaling its network of micro-fulfillment centers (MFCs) to handle this volume. As of May 2025, the network of 12 MFCs supported over 5,000 stores across the country. These high-tech facilities were fulfilling more than 3.5 million prescriptions weekly, which equates to approximately 16 million prescriptions filled each month.

This automation directly impacts the in-store experience by shifting workload away from the counter. At locations serviced by these facilities, MFCs manage approximately 40% of a store's total prescription volume. This operational shift is estimated to have reduced the cost per prescription by 13%. The initial goal was to have as much as half of the total prescription volume filled at these automated centers by 2025.

Metric	Value	Context/Date
Micro-Fulfillment Centers (MFCs) in Operation	12	As of May 2025
Stores Supported by MFC Network	Over 5,000	As of May 2025
Prescriptions Fulfilled Weekly (MFCs)	Over 3.5 million	As of May 2025
Cost Reduction per Prescription (Automation)	13%	Reported efficiency gain

Personalized digital engagement via the myWalgreens app and email

Digital channels are central to maintaining ongoing customer engagement and driving loyalty, primarily through the myWalgreens platform. The myWalgreens loyalty program boasts a substantial base, with more than 113 million active program members as of August 31, 2023. The Walgreens mobile app itself is trusted by over 13 million customers for managing health and shopping needs.

This digital relationship is structured around rewards and convenience:

• Earn unlimited 1% Walgreens Cash rewards storewide, even at the pharmacy.
• Earn unlimited 5% Walgreens Cash rewards per dollar on Walgreens branded products.
• Digital coupons and personalized deals are delivered to drive engagement and sales.

In the international segment, digital sales are also a key relationship driver; Boots.com sales grew 19.5% in fiscal 2025, making up over 20% of Boots' total retail sales.

Dedicated, high-touch relationships for specialty pharmacy and primary care patients

For complex health needs, the relationship shifts to a dedicated, high-touch model, primarily through the U.S. Healthcare segment investments. This segment is a growing part of the overall business, reporting first quarter fiscal 2025 sales of $2.2 billion.

The growth within these specialized areas demonstrates the focus on deeper patient relationships:

• VillageMD, the primary care network, saw sales increase 9% year-over-year in Q1 fiscal 2025.
• Shields Health Solutions, focused on specialty pharmacy, saw sales increase 30% in Q1 fiscal 2025.

This focus allows pharmacists to spend more time on patient advising and clinical needs, as automation handles routine tasks.

Self-service options for photo printing and online order pickup

Self-service options cater to customers prioritizing speed and control over their retail interactions. The digital platforms facilitate quick fulfillment choices that blend the online and physical experience. For customers using the app or website, pickup orders are advertised as ready in as little as 30 minutes curbside, drive-thru, or in-store. For those needing items delivered, the service promises delivery in as little as 1 hour.

The photo services remain a key self-service offering, with the Walgreens App allowing customers to bring ideas to life with custom photo prints, ready the same day.

Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Channels

You're looking at how Walgreens Boots Alliance, Inc. (WBA) gets its value proposition to the customer base as of late 2025. It's a mix of old-school real estate and digital integration, honestly, and the numbers show where the focus is shifting.

Physical Retail Stores (Walgreens and Boots UK)

The physical footprint remains the backbone, though it's actively being optimized. For Walgreens in the U.S., the count is tightening up as part of a major restructuring. As of December 1, 2025, there were 8,054 Walgreens pharmacies in the United States, following a plan to close 500 locations during fiscal year 2025. This optimization aims for a healthier store base, focusing investment on the profitable locations, which the CEO noted number around 6,000.

Across the pond, Boots UK is also managing its portfolio. While the company operated 1,840 stores as of August 31, 2024, a more recent figure from May 31, 2025, indicates they have over 1,800 stores, following a multi-year consolidation program. The Boots UK segment is a significant part of the international business, with its Q3 FY2025 sales growing 5.0 percent on a constant currency basis.

The in-store clinics represent a key channel for moving beyond pure retail. The Village Medical at Walgreens strategy saw an initial goal of 600 practices by 2025. However, the current strategy involves a reduction, with Walgreens announcing the closure of more than 160 VillageMD clinics as of early 2024, while evaluating options for other units like Summit Health-CityMD.

Here is a snapshot of the physical and digital scale as of the latest reporting periods:

Channel Component	Metric/Count	Latest Data Point/Date	Source Context
Walgreens U.S. Pharmacies	8,054	December 1, 2025	Current operating count
Walgreens FY2025 Planned Closures	500	Fiscal Year 2025	Part of a larger 1,200 store closure plan
Boots UK Stores	Over 1,800	May 31, 2025	Reflects portfolio management from a previous high of 2,232 in August 2022
VillageMD Clinic Reductions	Over 160 shut	Announced April 2024	Part of a reevaluation of the expansion plan

E-commerce platforms (Walgreens.com and Boots.com)

Digital sales are a growing component, particularly for Boots in the UK. Boots.com is cited as the UK's number one most visited health and beauty website. For the third quarter of fiscal 2025, Boots.com sales grew 18.7 percent year-over-year, representing 17 percent of Boots total retail sales. This growth is part of a trend, as Q2 FY2025 saw growth of 19.5 percent, making up over 20 percent of retail sales.

For Walgreens in the U.S., e-commerce is captured within the U.S. Retail Pharmacy segment comparable sales, which were up 10.3 percent in Q3 FY2025. The company's overall Q3 FY2025 sales reached $39.0 billion.

Mobile application for prescription management and digital coupons

The mobile channel is quantified through user engagement metrics, especially for the Boots brand. The Boots app had 8.4 million active users as of May 31, 2025. This digital tool supports prescription management, which is a core function. Across the U.S. pharmacy operations in Q1 FY2025, total prescriptions filled, adjusted to 30-day equivalents, reached 316.3 million, a 1.5 percent increase year-over-year. The company is number one for dispensing prescription items in the UK, handling millions per week.

The digital coupon and engagement strategy is also supported by the Boots Advantage Card program, which boasts over 17 million active members as of May 31, 2025.

Mail-order pharmacy services

While Walgreens U.S. comparable prescriptions filled (excluding immunizations) increased 3.9 percent in Q2 FY2025, specific, standalone financial or volume data for dedicated mail-order pharmacy services is not explicitly broken out in the latest public reports available to detail this channel separately from digitally initiated or standard retail pharmacy fulfillment.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Customer Segments

Walgreens Boots Alliance, Inc. (WBA) serves a highly diverse customer base across its U.S. Retail Pharmacy, International, and U.S. Healthcare segments.

The core customer base is anchored by the need for accessible health services and everyday retail convenience. As of August 31, 2024, approximately 78% of the U.S. population lived within a five-mile radius of a Walgreens or Duane Reade store, underscoring this mass-market reach.

The company also focuses on specific patient populations and strategic partners:

• Mass market retail shoppers seeking convenience and value.
• Chronic and acute patients requiring regular prescription medications.
• Price-sensitive consumers, including approximately 45% of low-income shoppers.
• Healthcare plan sponsors and providers utilizing CareCentrix and Shields.
• International retail and pharmacy customers (primarily Boots UK).

The scale of these segments can be seen in the following operational and financial metrics from the latest available reports for fiscal year 2025:

Customer Segment Focus	Metric	Value/Rate	Period/Date
Mass Market Retail Reach (US)	Number of U.S. Stores	More than 8,700	March 2025
Mass Market Retail Reach (US)	Population within 5 miles of a store	78%	August 31, 2024
Chronic/Acute Patients (US Pharmacy)	U.S. Retail Pharmacy Segment Revenue	$111.5 billion	Fiscal Year 2024
Healthcare Partners (U.S. Healthcare)	Shields Sales Growth (Q3 FY25)	Increased 24.8%	Q3 Fiscal 2025
Healthcare Partners (U.S. Healthcare)	CareCentrix Sales Growth (Q3 FY25)	Increased 11.6%	Q3 Fiscal 2025
International Customers (Boots UK)	Comparable Retail Sales Growth (Q3 FY25)	6.0%	Q3 Fiscal 2025
International Customers (Boots UK)	Boots.com Sales as % of Total Retail Sales	15%	Fiscal 2024
International Customers (Boots UK)	Online Sales as % of Total Retail Sales	20%	Three months ending February 2025

The U.S. Retail Pharmacy segment remains a massive driver, with comparable pharmacy sales showing strength, while the front-end retail sales have seen weakness. For the U.S. Healthcare segment in Q3 fiscal 2025, total sales were $2.1 billion.

The Boots UK segment continues to show growth momentum, with comparable pharmacy sales increasing 5.4% on a constant currency basis in Q3 fiscal 2025, and its digital channel is significant, with Boots.com sales growing 18.7% year-on-year in that quarter.

Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Cost Structure

You're looking at the cost side of Walgreens Boots Alliance, Inc. (WBA) as they navigate that tricky pivot from traditional retail to integrated healthcare. The numbers show where the biggest drains on cash and profitability are right now, based on the first nine months of fiscal year 2025 (9M FY2025) ending May 31, 2025.

The single largest component of cost is tied directly to sales volume. High cost of revenue, primarily product procurement for both prescription drugs and general retail inventory, eats up the vast majority of the top line. For 9M FY2025, the Gross Profit Margin was only 17.3%, meaning that roughly 82.7% of the $117.0 billion in total sales went to cover the cost of the goods sold. This high ratio reflects the lower-margin nature of high-volume prescription fulfillment and the competitive retail environment.

Next up are the fixed and semi-fixed costs associated with running the physical footprint. Significant store operating expenses are a constant pressure point. While specific rent figures aren't broken out separately in the latest summaries, payroll is a major driver of operating cost inflation. For instance, in the International segment during Q1 FY2025, cost inflation was primarily driven by payroll. The overall Operating Expenses for 9M FY2025 were reported as -$23.1B USD.

The balance sheet and cash flow statements are heavily impacted by one-time, non-cash charges and major legal settlements. These items significantly distort GAAP profitability. You saw a major hit in Q2 FY2025 with a $3.0 billion non-cash impairment charge related to VillageMD goodwill and other long-lived assets, which resulted in a $1.9 billion charge attributable to Walgreens Boots Alliance, net of tax and non-controlling interest. This reflects the ongoing strategic reassessment of the primary care investment.

Cash flow is definitely feeling the weight of litigation. Substantial legal payments are a major cash outflow. For the first nine months of fiscal 2025, operating cash flow was negatively impacted by $1.4 billion of legal payments, primarily related to Everly and opioid-related settlements. That's a huge chunk of cash used before even considering capital expenditures.

Here's a quick look at the key cost drivers for the 9M FY2025 period:

• Cost of Revenue (Implied): Approximately 82.7% of sales.
• Total Operating Expenses: $23.1 billion magnitude.
• Major Non-Cash Charge (Q2 FY2025): $3.0 billion VillageMD goodwill impairment.
• Cash Legal Payments (9M FY2025): $1.4 billion.

The company is actively investing in its future, which shows up as an expense category. Technology and digital transformation investments are part of the ongoing turnaround. For example, in Q1 FY2025, technology investments were cited as a factor partially offsetting adjusted operating income gains in the International segment, alongside cost inflation.

To put the scale of these costs into perspective, here is a comparison of key financial metrics for the nine-month period:

Metric	Amount (9M FY2025)	Context
Total Sales	$117.0 billion	Top-line revenue base.
Gross Profit	$20.220 billion	Sales minus Cost of Revenue.
Operating Loss (GAAP)	$5.8 billion	After all operating expenses, before interest/tax.
Net Loss (GAAP)	$3.3 billion	The bottom-line result.
Cash Used by Operating Activities (Net)	$245 million	Net cash flow from operations.

The pressure from these costs is evident in the GAAP results, where the operating loss for 9M FY2025 reached $5.8 billion. Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Revenue Streams

You're looking at how Walgreens Boots Alliance, Inc. (WBA) brings in the money, focusing strictly on the hard numbers as of late 2025. It's a mix of dispensing medicine and selling everyday goods, plus a growing healthcare services piece.

The largest chunk of revenue definitely comes from prescription drug sales, which is the core of the U.S. Retail Pharmacy segment. For the third quarter of fiscal 2025, this segment alone pulled in $30.7 billion in sales. Within that, pharmacy sales were up 11.8% year-over-year, largely thanks to branded drug inflation and the mix of drugs being dispensed.

Retail sales of front-end merchandise-think beauty, health, and wellness items you grab off the shelf-are another key stream, though they've seen some pressure. In that same Q3 FY2025 period, retail sales in the U.S. Retail Pharmacy segment actually declined by 5.3%. Still, the overall segment sales growth was strong enough to push total Q3 sales to $39.0 billion.

The U.S. Healthcare segment is a distinct revenue driver, which hit $2.1 billion in Q3 FY2025. This stream includes fees from providing clinical services, like immunizations and testing, though the segment's performance is tied to its specific businesses.

Here's a quick look at the segment sales breakdown from the third quarter of fiscal 2025:

Segment	Q3 FY2025 Sales Amount	Year-over-Year Sales Change (Reported)
U.S. Retail Pharmacy	$30.7 billion	Up 7.8%
International	$6.2 billion	Up 7.8%
U.S. Healthcare	$2.1 billion	Slightly down

For the full picture, Walgreens Boots Alliance, Inc. projected its full fiscal year 2025 sales to be between $147 billion and $151 billion. That's the big-picture target for the year, even though the company later withdrew formal guidance due to the pending acquisition.

Revenue from the U.S. Healthcare operations is diversified across its components, which contribute to those clinical services fees and other arrangements. You can see the variation in the Q3 performance of the sub-components:

• CareCentrix sales increased 11.6%.
• Shields sales increased 24.8%.
• VillageMD sales decreased 6.5%.